|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/53 | |
| A61K 31/7068 | |||
| A61P 35/00 | |||
| A61P 35/02 | |||
| A61K 45/06 | |||
| A61K 9/00 |
| (11) | Patento numeris | 3362070 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 16788866.8 |
| Europos patento paraiškos padavimo data | 2016-10-14 | |
| (97) | Europos patento paraiškos paskelbimo data | 2018-08-22 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2021-01-27 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2016/057102 |
| Data | 2016-10-14 |
| (87) | Numeris | WO 2017/066611 |
| Data | 2017-04-20 |
| (30) | Numeris | Data | Šalis |
| 201562242218 P | 2015-10-15 | US |
| (72) |
CHOPRA, Vivek, Saroj, Kumar, US
DIMARTINO,Jorge, US
KENVIN, Laurie, A., US
KNIGHT, Robert, Douglas, US
MACBETH, Kyle, US
VISWANADHAN, Krishnan, US
XU, Qiang, US
AGRESTA, Samuel, V., US
|
| (73) |
Celgene Corporation,
86 Morris Avenue, Summit, NJ 07901,
US
Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, MA 02139, US |
| (54) | COMBINATION OF A MUTANT ISOCITRATE DEHYDROGENASE 2 INHIBITOR WITH AZACITIDINE AND ITS USE FOR TREATING ACUTE MYELOGENOUS LEUKEMIA |
| COMBINATION OF A MUTANT ISOCITRATE DEHYDROGENASE 2 INHIBITOR WITH AZACITIDINE AND ITS USE FOR TREATING ACUTE MYELOGENOUS LEUKEMIA |